Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Multiple Myeloma 5Lymphoma, Non-Hodgkin 5Lymphoma, Extranodal NK-T-Cell 5Hodgkin Disease 5Recurrence 4Neuroblastoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Testicular Neoplasms 3Sezary Syndrome 3Neuroectodermal Tumors, Primitive, Peripheral 3Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Leukemia, Hairy Cell 3Dendritic Cell Sarcoma, Interdigitating 3Central Nervous System Neoplasms 3Teratoma 2Sarcoma 2

Interventions

Prednisone 1PE regimen 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Hormone Refractory Prostate Cancer × Etoposide × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡